Cannabinoid receptors as therapeutic targets for obesity and metabolic diseases

Current Opinion in Pharmacology

Volumn 6, Issue 6, 2006, Pages 586-591

  Bellocchio, Luigi ^a   Mancini, Giacomo ^a   Vicennati, Valentina ^a   Pasquali, Renato ^a   Pagotto, Uberto ^a  

^a CRBA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; DRONABINOL; ENDOCANNABINOID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; PLACEBO; RIMONABANT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADIPOCYTE; BLOOD PRESSURE REGULATION; BODY WEIGHT; CALORIC INTAKE; CELL METABOLISM; CLINICAL TRIAL; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DRUG SAFETY; DRUG TARGETING; DYSLIPIDEMIA; ENDOCRINE CELL; ENERGY BALANCE; FEEDING BEHAVIOR; FOOD INTAKE; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HUMAN; HYPOTHALAMUS; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIVER CELL; LOW CALORY DIET; METABOLIC DISORDER; METABOLIC REGULATION; MUSCLE CELL; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PALATABILITY; PANCREAS CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; VOMITING; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

ANIMALS; APPETITE REGULATION; ENDOCANNABINOIDS; HUMANS; METABOLIC DISEASES; OBESITY; RECEPTOR, CANNABINOID, CB1; RECEPTORS, CANNABINOID;

EID: 33750509664     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2006.09.001     Document Type: Review

References (46)

1. Gaoni Y., and Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 86 (1964) 1646-1647
2. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., and Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346 (1990) 561-564
3. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., and Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258 (1992) 1946-1949
4. Mechoulam R., Ben-Shabat S., Hanus L., Ligumsky M., Kaminski N.E., Schatz A.R., Gopher A., Almog S., Martin B.R., Compton D.R., et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50 (1995) 83-90
5. Sugiura T., Kondo S., Sukagawa A., Nakane S., Shinoda A., Itoh K., Yamashita A., and Waku K. 2-Arachidonyl glycerol: a possibile endogenous cannabinoid receptor ligand in the brain. Biochem Biophys Res Commun 215 (1995) 89-97
6. Kogan N.M., and Mechoulam R. The chemistry of endocannabinoids. J Endocrinol Invest 29 Suppl 3 (2006) 3-14. This is a complete overview about endogenous and exogenous cannabinoids.
7. Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4 (2003) 873-884
8. Kirkham T.C., Williams C.M., Fezza F., and Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 136 (2002) 550-557
9. Di Marzo V., and Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 8 (2005) 585-589. This is an up-to-date review in which the hypothesis of endocannabinoid overactivation is particularly emphasised.
10. Pagotto U., Marsicano G., Cota D., Lutz B., and Pasquali R. The emerging role of endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 27 (2006) 73-100. This is a complete overview of the role of endocannabinoids in the regulation of food intake and peripheral metabolism. A summary of the experiments performed in the past 40 years, in which exogenous cannabinoids were tested to modulate appetite, is also provided.
11. Cota D., Tschoep M.H., Horvath T.L., and Levine A.S. Cannabinoids, opioids and eating behavior: the molecular face of hedonism?. Brain Res Brain Res Rev 51 (2006) 85-107. An up-to-date review in which the role of endocannabinoids in the process of reward is examined in the light of their cross-talk with other neurtransmitters and neuropeptides.
12. Flier J.S. Obesity wars: molecular progress confronts an expanding epidemic. Cell 116 (2004) 337-350
13. Seeley R.J., and York D.A. Fuel sensing and the central nervous system (CNS): implications for the regulation of energy balance and the treatment for obesity. Obes Rev 6 (2005) 259-265
14. Hanus L., Avraham Y., Ben-Shushan D., Zolotarev O., Berry E.M., and Mechoulam R. Short term fasting and prolonged semistarvation have opposite effects on 2-AG levels in the mouse brain. Brain Res 983 (2003) 144-151
15. Breivogel C.S., and Childers S.R. The functional neuroanatomy of brain cannabinoid receptor. Neurobiol Dis 5 (1998) 417-431
16. Breivogel C.S., Selley D.E., and Childers S.R. Cannabinoid receptor agonist efficacy for stimulating [35S]GTPgammaS binding to rat cerebellar membranes correlates with agonist-induced decreases in GDP affinity. J Biol Chem 273 (1998) 16865-16873
17. Di Marzo V., Goparaju S.K., Wang L., Liu J., Batkai S., Jarai Z., Fezza F., Miura G.I., Palmiter R.D., Sugiura T., and Kunos G. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410 (2001) 822-825
18. Jo Y.H., Chen Y.J., Talmage D.A., and Role L.W. Integration of leptin signalling in an appetite- related neural circuit. Neuron 48 (2005) 1055-1066
19. Cota D., Marsicano G., Tschoep M., Gruebler Y., Flachskamm C., Schubert M., Auer D., Yassouridis A., Thone-Reineke C., Ortmann S., et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 112 (2003) 423-431
20. Gamber K.M., Macarthur H., and Westfall T.C. Cannabinoids augment the release of neuropeptide Y in the rat hypotalamus. Neuropharmacology 49 (2005) 646-652
21. Tucci S.A., Rogers E.K., Korbonits M., and Kirkham T.C. The cannabinoid receptor antagonist SR141716 blocks the orexigenic effect of intrahypothalamic ghrelin. Br J Pharmacol 143 (2004) 520-523
22. Rigamonti A., Giordani C., Bonomo S.M., Cella S.G., and Muller E.E. Early tolerance to the hypophagic effect of the cannabinoid receptor antagonist SR141716 does not impede blockade of an orexigenic stimulus. Eur J Pharmacol 542 (2006) 116-120
23. Lopez M., Tovar S., Vasquez M.J., and Dieguez C. Sensing the fat: fatty acid metabolism in the hypothalamus and the melanocortin system. Peptides 26 (2005) 1753-1758
24. Osei-Hyiaman D., DePetrillo M., Pacher P., Liu J., Radaeva S., Batkai S., Harvey-White J., Mackie K., Offertaler L., Wang L., and Kunos G. Endocannabinoids activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet induced obesity. J Clin Invest 115 (2005) 1298-1305. This is the first report on the role of endocannabinoids in modulating de novo fatty acid synthesis in the liver.
25. Kola B., Hubina E., Tucci S.A., Kirkham T.C., Garcia E.A., Mitchell S.E., Williams L.M., Hawley S.A., Hardie D.G., Grossman A.B., and Korbonits M. Moreover the exact title and reference are: Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. J Biol Chem 280 (2005) 25196-25201. This is first study in which a link between cannabinoids and AMP-activated protein kinase was proposed.
26. Greenberg I., Kuehnle J., Mendelson J.H., and Bernstein J.G. Effects of marijuana use on body weight and caloric intake in humans. Psycopharmacology (Berlin) 49 (1976) 79-84
27. Colombo G., Agabio R., Diaz G., Lobina C., and Gessa G.L. Appetite suppression and weight gain loss after the cannabinoid antagonist SR141716. Life Sci 63 (1998) PL113-PL117
28. Ravinet Trillou C., Arnone M., Delgorge C., Gonalons N., Keane P., Maffrand J.P., and Soubrie P. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet induced obese mice. Am J Physiol Regul Integr Comp Physiol 284 (2003) R345-R353
29. Hildebrandt A.L., Kelly-Sullivan D.M., and Black S.C. Anti-obesity effects of chronic CB1 receptor antagonist treatment in diet induced obese mice. Eur J Pharmacol 462 (2003) 125-132
30. Ravinet Trillou C., Delgorge C., Menet C., Arnone M., and Soubrie P. CB1 cannabinoid receptor knock out in mice leads to leanness, resistance to diet induced obesity and enhanced leptin sensivity. Int J Obes 24 (2004) 640-648
31. Poirier B., Bidouard J.P., Cadrouvele C., Marniquet X., Staels B., O'Connor S.E., Janiak P., and Herbert J.M. The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes Metab 7 (2005) 65-72
32. Bensaid M., Gary-Bobo M., Esclangon A., Maffrand J.P., Le Fur G., Oury-Donat F., and Soubrie P. The cannabinoid CB1 receptor antagonist SR141716 increased Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 63 (2003) 908-914
33. Jbilo O., Ravinet-Trillou C., Arnone M., Buisson I., Bribes E., Peleraux A., Penarier G., Soubrie P., Le Fur G., Galiegue S., and Casellas P. The CB1 receptor antagonist rimonabant reverse the diet induced obesity phenotype trough regulation of lipolysis and energy balance. FASEB J 19 (2005) 1567-1569. This is a paper in which a large series of genes was shown to be modulated by rimonabant treatment by using DNA chip technology.
34. Perwitz N., Fasshauer M., and Klein J. Cannabinoid receptor signalling directly inhibits thermogenesis and alters expression of adiponectin and visfatin. Horm Metab Res 38 (2006) 356-358
35. Gary-Bobo M., Elachouri G., Scatton B., Le Fur G., Oury-Donat F., and Bensaid M. The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes. Mol Pharmacol 69 (2006) 471-478
36. Matias I., Gonthier M.P., Orlando P., Martiadis V., De Petrocellis L., Cervino C., Petrosino P., Pasquali R., Maj M., Pagotto U., and Di Marzo V. Regulation, function and dysregulation of endocannabinoids in models of adipose and β-pancreatic cells and in obesity and hyperglicemia. J Clin Endocrinol Metab 91 (2006) 3171-3180. This is a report showing the increase in endocannabinoids from visceral depots derived from obese patients.
37. Gomez R., Navarro M., Ferrer B., Trigo J.M., Bilbao A., Del Arco I., Cippitelli A., Nava F., Piomelli D., and Rodriguez de Fonseca F. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 22 (2002) 9612-9617
38. Burdyga G., Lal S., Varro A., Dimaline R., Thompson D.G., and Dockray G.J. Expression of cannabinoid CB1 receptors by vagal afferent neurons is inhibited by cholecystokinin. J Neurosci 24 (2004) 2708-2715
39. Liu Y.L., Connoley I.P., Wilson C.A., and Stock M.J. Effects of CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in lep(ob)/lep(ob) mice. Int J Obes Relat Metab Disord 29 (2005) 183-187
40. 1 receptors in endocrine pancreatic cells.
41. Bermudez-Silva F.J., Serrano A., Diaz-Molina F.J., Sanchez Vera I., Juan-Pico P., Nadal A., Fuentes E., and Rodriguez de Fonseca F. Activation of cannabinoid CB1 receptors induces glucose intolerance in rats. Eur J Pharmacol 531 (2006) 282-284
42. 1 receptors in human adipocytes; increased circulating endocannabinoid levels were also demonstrated in obese patients.
43. Sipe J.C., Waalen J., Gerber A.L., and Beutler E. Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH). Int J Obes 29 (2005) 755-759
44. Van Gaal L.F., Rissanen A.M., Scheen A.J., Ziegler O., Rossner S., and for the RIO-Europe study Group. Effects of the cannabinoid CB1 receptor blocker rimonabant on weight reduction and cardiovascular risk factor in overweight patients: 1 year experience from the RIO-Europe Study. Lancet 365 (2005) 1389-1397. This is the first study published concerning a Phase III trial in which rimonabant was tested to tackle obesity.
45. Despres J.P., Golay A., Sjostrom L., and for the RIO-Lipids study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353 (2005) 2121-2134. This is the second study published concerning a Phase III trial in which rimonabant was tested to tackle obesity and/or over-weight in association with dyslipidemia. This report also provides data on changes in adiponectin levels after rimonabant treatment.
46. Pi-Sunyer F.X., Aronne L.J., Heshmati H.M., Devin J., Rosenstock J., and for the RIO-North America study Group. Effects of rimonabant, a cannabinoid-1 receptor blocker. On weight and cardiometabolic risk factors in overweight or obese patients. J Am Med Assoc 295 (2006) 761-775. This is the first study in which two-year rimonabant treatment was proposed for tackling obesity. In this paper, re-randomization of patients also occurred at the end of the first year: patients randomized during the first year on rimonabant were allocated placebo during the second year, making it possible to detect the weight re-gain effect after discontinuation of the drug.